Pharmaceutical companies Pfizer and Biotech on Thursday announced the start of trials on the efficacy and safety of the third dose of their coronavirus vaccine.
The study is conducted to study the effect of the vaccine in the fight against new variants of the coronavirus.
“Pfizer and BioNTech today announced that they had begun an evaluation of the safety and immunogenicity of the third dose of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) to determine the effect of the COVID-19 immunity booster caused by already circulating and potentially novel SARS-CoV-2 variants,” Pfizer said in a statement on its website.
It is noted that at least 144 participants will take part in the trial in two age groups – from 18 to 55 years old and people aged 65 to 85. The third dose of the drug will be given to those who have already received two vaccinations 6 to 12 months ago. Their condition is studied directly when receiving the third dose of the drug, a week later and a month later. Doctors will continue to monitor the participants in the trials for two years, as planned during the first phases of the trials.